Skip to content

Effect of transcutaneous auricular vagus nerve stimulation on neuropathic pain and cognitive impairment induced by neuropathic pain

The effect of transcutaneous auricular vagus nerve stimulation on neuropathic pain and the mechanism of inflammation regulation

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089232
Enrollment
Unknown
Registered
2024-09-04
Start date
2024-09-30
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Control group:Drug therapy + sham stimulation
taVNS group:Drug therapy + taVNS

Sponsors

Xuzhou First People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years of age with diagnosed postherpetic neuralgia

Exclusion criteria

Exclusion criteria: a <18 years old; b Patients with substance dependence; c Patients with major depression or neuropsychiatric diseases such as serious suicidal tendencies: d Patients with serious physical diseases such as cardiovascular and cerebrovascular diseases, liver and kidney dysfunction and other important organs; e Patients cannot adhere to treatment due to long distance or other reasons f Patients with visual, auditory and language impairment g Patients with metal implants, ear implants, or physical changes in the face or brain h Bradycardia (HR<50 beats/min)

Design outcomes

Primary

MeasureTime frame
numerical rating scale of pain;Short-form McGill Pain Questionnaire;Wechsler Memory Scale;

Secondary

MeasureTime frame
Beck Anxiety Inventory;Beck Depression Inventory;

Countries

China

Contacts

Public ContactRui Yao

Xuzhou First People’s Hospital

yaorui_edu@163.com+86 187 6143 1804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026